APPLICATION OF THE COMBINATION OF UDENAFIL AND ALFUZOSIN OR OXIBUTININ FOR THE TREATMENT OF A HYPERACTIVE URINARY BLADDER

摘要

1. A pharmaceutical composition containing two active substances, udenafil and either alfuzosin, or an antimuscarinic agent selected from the group of oxybutynin, tolterodine, darifenacin, solifenacin and trospium, or a pharmaceutically acceptable salt, solvate, prodrug or hydrate of any of these substances. ! 2. The pharmaceutical composition according to claim 1, in which the antimuscarinic agent is oxybutynin or a pharmaceutically acceptable salt, solvate, prodrug or hydrate thereof. ! 3. The pharmaceutical composition according to claim 1, made in the form of a standard dosage form. ! 4. The pharmaceutical composition according to claim 1, in which each active substance is contained in a separate dosage form. ! 5. The pharmaceutical composition according to claim 1, in which the formulation of the two active substances is developed in the form of a solid dosage form. ! 6. A method of treating an overactive bladder, benign prostatic hyperplasia and lower urinary tract symptoms, comprising administering to a patient in need of a therapeutically effective amount of a composition containing two active substances: udenafil and either alfuzosin, or an antimuscarinic agent selected from the group of oxybutynin, tolteradine, darifenacin , solifenacin, and trospium, or a pharmaceutically acceptable salt, solvate, prodrug, or hydrate of any of these substances. ! 7. The method according to claim 6, in which the formulation of the two active substances is developed in the form of a standard dosage form. ! 8. The method according to claim 6, in which the formulation of each active substance is developed in the form of separate dosage forms. ! 9. The method according to claim 6, in which two active substances